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A subset of patients with gastro-oesophageal reflux disease (GERD) does not
achieve complete symptom resolution with proton pump inhibitor (PPI) therapy.
The factors which affect response to PPI therapy in GERD patients remain unclear.
Aims
To determine the prevalence and impact of irritable bowel syndrome
(IBS) and psychological distress (PD) on GERD symptoms and disease-
specific quality of life (QoL) before and after PPI therapy and to assess
the same outcomes before and after PPI therapy in non-erosive reflux
disease (NERD) and erosive oesophagitis (EO) GERD patients.
Methods
Patients undergoing oesophago-gastroduodenoscopy (OGD) for heart-
burn were recruited. Participants completed validated surveys: Digestive
Health Symptom Index, Reflux Disease Questionnaire, Quality of Life in
Reflux and Dyspepsia and Brief Symptom Inventory (BSI). IBS was
defined as >3 Manning criteria and PD as BSI score >63. At OGD,
patients were classified as NERD or EO. Patients were treated with rab-
eprazole 20 mg ⁄day for 8 weeks before completing follow-up surveys.
Results
Of 132 GERD patients enrolled, 101 completed the study. The prevalence rates of
IBS and PD were 36% and 41%, respectively. IBS independently predicted worse
QoL before and after PPI therapy. PD independently predicted worse GERD
symptoms and QoL before and after PPI therapy. There were no differences in
symptoms or QoL between NERD and EO patients before or after PPI therapy.
Conclusions
IBS and PD impacted GERD symptoms and QoL before and after PPI
therapy. Symptoms and QoL before and after PPI therapy were similar
in NERD and EO patients.
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INTRODUCTION
Symptoms of gastro-oesophageal reflux disease
(GERD) including heartburn and regurgitation are
common, affecting approximately 20% of the general
population on a weekly basis.1, 2 A variety of medi-
cations are currently available to treat GERD. Proton
pump inhibitors (PPIs) have proven more effective
than histamine receptor antagonists and placebo
both for the healing of erosive oesophagitis (EO) and
for improvement of symptoms.3, 4 Although a major-
ity of treated patients experience symptom improve-
ment or resolution, a significant subset report
persistent symptoms despite PPI therapy. The predic-
tors of response to PPI therapy have been only par-
tially characterized. Practical issues can confound
the effectiveness of PPI therapy. For example, medi-
cal noncompliance is an important issue for some
patients. The manner in which a patient is instructed
to take PPI therapy can also influence treatment
efficacy.5 Further, patients with typical GERD symp-
toms including heartburn and regurgitation are more
likely to respond to PPI therapy than those with
extraoesophageal symptoms such as asthma, hoarse-
ness or cough.6, 7
When patients fail to improve with PPI therapy,
detailed diagnostic testing with ambulatory oesopha-
geal pH monitoring and ⁄ or impedence testing to
exclude persistent acid or non-acid reflux have been
recommended.8 Despite such invasive testing, more
than half of patients will have no identifiable relation-
ship between acid or non-acid reflux episodes and
GERD symptoms.9, 10 In aggregate, these observations
underscore the importance of understanding the fac-
tors which influence response of patients with GERD
symptoms to PPI therapy.
Patients with symptoms suggestive of GERD often
report multiple symptoms referable to the gastrointes-
tinal (GI) tract. For example, a recent study reported
that a significant proportion of patients with GERD
symptoms also experienced symptoms compatible with
the diagnosis of the irritable bowel syndrome (IBS)
and functional dyspepsia.11 Co-morbid psychological
distress (PD) is reportedly more common in patients
with GERD symptoms.12–16 A recent work suggests
that major life stressors are associated with more
severe and frequent GERD symptoms.17 Whether co-
morbid IBS or PD influences the response to PPI ther-
apy in patients with GERD symptoms has not been
prospectively studied.
Traditionally, patients with GERD have been classi-
fied as suffering from either EO or non-erosive reflux
disease (NERD) by upper endoscopy. There is some
evidence to suggest that patients with EO are more
likely to respond to PPI therapy than those with
NERD.18 As EO is almost uniformly acid-related while
NERD probably represents a heterogeneous group of
abnormalities, this suggestion is mechanistically
attractive. Unfortunately, there are few published stud-
ies which have directly compared the efficacy of PPI
therapy on heartburn relief in EO and NERD patients
from the same population.19, 20 Further, a number of
practical issues limit a clinician’s ability to distinguish
between patients with EO and patients with NERD in
clinical practice.21 For example, a vast majority of
patients with GERD symptoms never undergo upper
endoscopy. For the minority of affected patients who
undergo upper endoscopy, the procedure is typically
performed after initiation of PPI therapy, which would
be expected to confound the endoscopist’s ability to
detect EO.
The aims of this study were to identify prospectively
the percentage of GERD patients with co-morbid IBS
and PD and to determine the impact of these co-mor-
bidities on response of reflux symptoms to PPI ther-
apy. We further assessed baseline symptom severity
and quality of life (QoL) before and after PPI therapy
in patients stratified by the presence or absence of EO.
MATERIALS AND METHODS
Patient population
Consecutive patients undergoing oesophago-gastrodu-
odenoscopy (OGD) for the purpose of evaluating typi-
cal GERD symptoms including heartburn and ⁄ or
regurgitation at the Medical Procedures Unit of the
University of Michigan Health System were considered
for enrolment in this study. To be eligible, patients
had to be greater than 18 years of age and able to
understand and provide written informed consent.
They had to report heartburn and ⁄ or regurgitation as
their primary complaint. They also had to experience
these symptoms more than twice per week for at least
2 months. Heartburn was defined as a burning sensa-
tion beginning in the upper abdomen or lower chest
and rising towards the neck. We defined regurgitation
as an effortless return of gastric contents into
the pharynx without nausea, retching or abdominal
contractions.
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Patients who had taken a PPI for any reason within
2 weeks of their upper endoscopy were excluded from
this study. Patients using histamine-2 receptor antago-
nists were eligible for enrolment. Also, patients were
not eligible if they were currently taking nonsteroidal
anti-inflammatory drugs or antidepressant medica-
tions. Other exclusion criteria included: a recent his-
tory of exertional chest pain, decompensated heart
failure, renal disease, pulmonary disease, melena or
hematochezia, a known Zencker’s diverticulum, GI
malignancy, significant liver disease (evidence of
coagulopathy, encephalopathy, ascites or varices),
known bleeding disorder or active peptic ulcer disease
(PUD) at OGD.
Protocol
Eligible patients who agreed to participate were asked
to complete a series of validated survey instruments to
assess:
1. reflux symptoms (Reflux Disease Questionnaire,
RDQ includes total GERD score; heartburn, regurgita-
tion and dyspepsia scales);22
2. gastrointestinal symptoms (Digestive Health Status
Instrument, DHSI includes GERD ⁄ ulcer, IBS-diarrhoea
predominant, IBS-constipation predominant, dysmotil-
ity and pain experience scales);23, 24
3. reflux and dyspepsia associated quality of life
(Quality of Life in Reflux and Dyspepsia, QoLRAD
includes total QoLRAD score; emotional distress, sleep
disturbances, food ⁄ drink problems, physical ⁄ social
functioning and vitality scales);25
4. psychological distress [Brief Symptom Inventory,
BSI included nine primary scales from which a Global
Severity Index (GSI) was calculated].26
Upon completion of the surveys, OGD was per-
formed at which time, the presence or absence of EO
was recorded. Patients were informed of any findings
at endoscopy. All patients were then treated with open
label rabeprazole 20 mg ⁄ day (Esai Co., Ltd, Tokyo,
Japan) for 8 weeks. Upon completion of rabeprazole
therapy, enrolees were seen by an investigator and
asked to repeat three of the survey instruments (RDQ,
DHSI and QoLRAD). During this visit, compliance with
PPI therapy was assessed by interview and pill count.
Figure 1 provides a flow diagram for the study.
Study definitions
At OGD, the presence and severity of EO were deter-
mined using the Los Angeles classification.27 All par-
ticipants were evaluated for the presence of co-morbid
IBS and psychological distress. Co-morbid IBS was
defined as more than 3 Manning criteria on the
DHSI.28 The construct of the survey also allowed us to
assess diarrhoea and constipation related symptoms in
patients with IBS. Generalized psychological distress
was defined as a GSI score higher than 63 on the BSI
or a score of ‡63 on two of the primary scales.26
Power calculation
We performed power calculations for the treatment
response to PPI therapy amongst patients with and
without IBS and for patients with and without EO.
To compare symptom resolution with PPI in GERD
patients with and without IBS, we had to make several
assumptions based largely on expert opinion. We
assumed that 60% of GERD patients without IBS
would experience symptom resolution with PPI
GERD symptoms/132 patients 
DHSI/RDQ/QoLRAD/BSI
OGD/101 patients 
Rabeprazole × 8 weeks Rabeprazole × 8 weeks
8-week follow-up
DHSI, RDQ, QoLRAD, 
8-week follow-up





Figure 1. Study protocol.
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therapy while 30% of GERD patients with IBS would
achieve this outcome following PPI therapy. We also
assumed that 40% of GERD patients would qualify for
the diagnosis of IBS.29 Given these assumptions, a
sample size of 90 patients would provide 81% power
and 120 patients would provide 91% power to detect
significant differences between groups.
For the comparison of symptom resolution with PPI
therapy in GERD patients with and without EO, we
assumed that 57% of patients with EO vs. 37% of
patients with NERD would achieve symptom resolution
with PPI therapy18 and that one-third of patients with
GERD symptoms would have EO (based upon unpub-
lished data from our endoscopic database). Given these
assumptions, a sample size of 216 patients would pro-
vide us with 80% power, while a sample size of 291
would provide 90% power to detect significant differ-
ences between groups.
Statistical analysis
Responses to questionnaires before and after PPI ther-
apy or based on the presence or absence of IBS, PD or
EO were compared using ANOVA. A P-value of less than
0.05 defined a statistically significant difference
between conditions.
Multivariable linear regression was performed on
reflux symptoms from the RDQ, DHSI and QoLRAD for
the presence of IBS as an independent factor, control-
ling for age, gender and the presence of psychological
distress. A similar analysis was performed for the pres-
ence of psychological distress as an independent fac-
tor, controlling for age, gender and the presence of
IBS.
RESULTS
In all, 132 enrolled patients completed the first set of
surveys and received study medication between June
2002 and July 2006. It should be noted that there is
an ‘open access’ policy at the University of Michigan,
which allows primary care physicians to order OGD
without prior consultation with a gastroenterologist.
Approximately 40% of study participants were sched-
uled directly through their primary care provider. The
remainder of the study population was referred from
the Gastroenterology Clinics of the University of Mich-
igan Health System. Of the 132 patients initially
enrolled, 31 patients (23.5%) were excluded because of
active PUD at OGD, being lost to follow-up or failure
to complete the second set of surveys. These patients
were labelled as protocol violations and excluded from
the final analysis.
Prevalence of co-morbid IBS and PD
Using a threshold of greater than 3 Manning criteria,
the prevalence of co-morbid IBS in the total popula-
tion of GERD patients was 35.6%. There was no differ-
ence in the prevalence of IBS in patients with NERD
or EO (35% and 36%, NS). The prevalence of psycho-
logical distress in the overall population of GERD
patients was 40.6%. There was no significant differ-
ence in the prevalence of psychological distress in
those with NERD vs. EO (41% vs. 37%, NS).
Impact of co-morbid IBS on GERD symptoms
and QoL
Gastro-oesophageal reflux disease-related symptom
burden (DHSI, RDQ) and disease-specific QoL (QoL-
RAD) were assessed in patients stratified by the pres-
ence or absence of co-morbid IBS. At baseline, GERD
patients with co-morbid IBS had significantly greater
GERD-related symptom burden on both the GER-
D + ulcer subscale of DHSI and total GERD score of
RDQ than GERD patients without IBS (P = 0.014 and
P = 0.022, respectively). On both of these survey
instruments, higher scores suggest a greater symptom
burden. Controlling for age, gender and psychological
distress, IBS was associated with worse GERD ⁄ ulcer
symptoms on the DHSI (+7.77, P = 0.04), and trended
towards worse GERD symptoms on the RDQ (+3.75,
P = 0.06). After PPI therapy, there were significant
improvements in GERD symptoms in patients with and
without co-morbid IBS (P < 0.0001), but there were no
significant differences in the magnitudes of improve-
ment in DHSI and RDQ scores among patients with
co-morbid IBS compared to patients without IBS
()3.85, P = 0.41 and )0.80, P = 0.73, respectively,
controlling for age, gender and psychological distress).
The presence of IBS was not associated with the post-
therapy DHSI and RDQ scores, after controlling for
age, gender and psychological distress ()1.38,
P = 0.72 and +1.44, P = 0.48, respectively) (Table 1).
Gastro-oesophageal reflux disease patients with co-
morbid IBS had significantly worse disease-specific
QoL by total QoLRAD score ()0.95, P = 0.0001) and
for each subscale (P < 0.003 for each) compared with
GERD patients without co-morbid IBS, controlling for
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age, gender and psychological distress. Following PPI
therapy, patients with and without co-morbid IBS
experienced significant improvements in disease-spe-
cific QoL as measured by total QoLRAD score
(P < 0.0001) and all subscales (P < 0.001). The magni-
tude of improvement in QoLRAD score was greater in
patients with co-morbid IBS than in those without
IBS, controlling for age, gender and psychological dis-
tress (+0.53, P < 0.025). Post-treatment total QoLRAD
and subscale scores were lower in patients with co-
morbid IBS than in those without IBS, although these
differences were not statistically significant (Table 2).
Impact of co-morbid PD on GERD symptoms
and QoL
Before PPI treatment, co-morbid psychological dis-
tress was associated with a greater GERD symptom
burden (GERD + ulcer subscale of DHSI +7.80,
P = 0.021; GERD score of RDQ +3.1, P = 0.077, both
controlling for age, gender and IBS). After 8 weeks of
PPI therapy, there were statistically and clinically sig-
nificant reductions in symptom burden as measured
by DHSI compared with baseline in patients with and
without psychological distress (P = 0.0001). There was
no significant association between co-morbid psycho-
logical distress and the magnitude of change in the
DHSI GERD ⁄ ulcer score (P = 0.763) or RDQ
(P = 0.216), controlling for age, gender and IBS.
Post-treatment GERD symptom burden remained sig-
nificantly greater for patients with co-morbid psycho-
logical distress compared with those without
psychological distress (GERD + ulcer subscale of DHSI
+9.6, P = 0.012, GERD score of RDQ +4.90,
P = 0.007, controlling for age, gender and IBS)
(Table 3).
Patients with co-morbid psychological distress had
significantly worse disease-specific QoL (QoLRAD
)0.98, P < 0.0001) at baseline than those without psy-
chological distress, controlling for age, gender and
IBS. Post-treatment disease-specific QoL as measured
by total QoLRAD ()0.74, P = 0.006) and all subscale
scores (P < 0.03 for each) were significantly lower in
patients with co-morbid psychological distress com-
pared with those without psychological distress. How-
ever, there was no significant difference in the
magnitude of change in QoLRAD scores following PPI
therapy in patients with or without co-morbid psycho-
logical distress (P = 0.278) (Table 4).
Table 1. Digestive Health Status Instrument (DHSI)-
gastro-oesophageal reflux disease (GERD) + Ulcer and
Reflux Disease Questionnaire (RDQ)-GERD scores in GERD
patients with and without co-morbid irritable bowel syn-








Baseline 41.8 (19.4) 33.3 (19.1) 0.014





Baseline 17.1 (9.5) 13.0 (9.4) 0.022




Table 2. Quality of Life in Reflux and Dyspepsia (QoL-
RAD) scores in gastro-oesophageal reflux disease patients
with and without co-morbid irritable bowel syndrome







Baseline 3.35 (1.28) 4.26 (1.16) 0.0001
Follow-up 4.79 (1.42) 5.17 (1.08) 0.12
P-value <0.0001 <0.0001
Table 3. Digestive Health Status Instrument (DHSI)-
gastro-oesophageal reflux disease (GERD) + Ulcer and
Reflux Disease Questionnaire (RDQ)-GERD scores in GERD
patients with and without co-morbid psychological dis-








Baseline 40.1 (19.4) 32.3 (18.7) 0.021





Baseline 16.1 (10.0) 13.0 (9.1) 0.077
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NERD vs. EO
Of the 101 patients who successfully completed the
protocol, 67 had no evidence of oesophagitis and 34
had EO found during OGD. Details regarding patients
in the two groups are provided in Table 5. Patients
enrolled in this study had a high baseline GERD-
related symptom burden as assessed by the DHSI and
RDQ. There was no significant difference in baseline
GERD symptoms in patients with NERD or EO as mea-
sured by the GERD + ulcer subscale of DHSI or the
overall GERD, heartburn or regurgitation subscales of
RDQ. After 8 weeks of PPI therapy, GERD symptoms
significantly improved from baseline in patients with
NERD (P < 0.0001) and EO (P < 0.0006). In fact, post-
treatment symptom scores were similar to those
reported in persons with no GERD.23, 24 No significant
differences in GERD symptom scores on DHSI or RDQ
were observed in patients with NERD or EO following
PPI therapy (Table 6).
Regarding disease-specific QoL, no significant differ-
ences between NERD and EO patients were observed in
total QoLRAD scores or any of its subscales (emotions,
sleep, food, physical ⁄ social functioning, vitality) at
baseline. Both patients with NERD and EO enjoyed sig-
nificant increases in total QoLRAD scores and for all
subscales after PPI therapy signifying statistically and
clinically significant improvements in disease-specific
QoL. No significant differences in QoLRAD scores
between the two groups were observed following PPI
therapy.
DISCUSSION
There is broad consensus that PPIs provide the most
effective form of medical therapy for patients with
symptoms suggestive of GERD.4, 27, 30 PPI therapy is
highly effective at healing EO. However, symptom res-
olution rates following PPI therapy in patients with
GERD symptoms have typically been lower than rates
of EO healing. Predictors of response to PPI therapy in
GERD patients remain poorly elucidated.
Considerable overlap of different GI symptoms has
been reported in recent community-based studies.11, 31
Other studies have reported a significant overlap
between GERD and IBS with prevalence rates of IBS in
Table 4. Quality of Life in Reflux and Dyspepsia (QoL-
RAD) scores in gastro-oesophageal reflux disease patients
with and without co-morbid psychological distress (PD)







Baseline 3.35 (1.26) 4.33 (1.13) <0.0001
Follow-up 4.61 (1.54) 5.35 (0.74) 0.006
P-value <0.0001 <0.0001
PD = BSI ‡ 63 or two primary scale scores ‡63.
Table 5. Demographics of patients with gastro-oesopha-
geal reflux disease symptoms
NERD EO P-value
Number of patients 67 34
Mean age 48.4 49.4 NS
Age range 18–77 23–73
Percent female (# female) 64.2% (43) 32.5% (11) <0.05
Percent with hiatal hernia 47.8% (32) 47% (16) NS





NERD, non-erosive reflux disease; EO, erosive oesophagitis.
Table 6. Digestive Health Status Instrument (DHSI)-gas-
tro-oesophageal reflux disease (GERD) + Ulcers subscale,
and Reflux Disease Questionnaire (RDQ) subscale scores
in erosive oesophagitis (EO) and non-erosive reflux dis-








Baseline 40.2 (17.3) 38.7 (18.9) 0.6747
Follow-up 18.9 (22.1) 17.3 (16.9) 0.7028
P-value <0.0001 <0.0001
RDQ-GERD
Baseline 17.1 (9.1) 15.9 (9.0) 0.5293
Follow-up 9.0 (11.1) 6.4 (7.2) 0.2512
P-value <0.0006 <0.0001
RDQ-heartburn
Baseline 8.8 (6.1) 7.5 (5.6) 0.3178
Follow-up 4.6 (6.3) 2.7 (3.9) 0.1512
P-value 0.0027 <0.0001
RDQ-regurgitation
Baseline 8.4 (5.0) 8.4 (5.5) 0.9910
Follow-up 4.6 (5.2) 3.7 (4.1) 0.3806
P-value 0.002 <0.0001
478 B . NOJKOV et al.
ª 2008 The Authors, Aliment Pharmacol Ther 27, 473–482
Journal compilation ª 2008 Blackwell Publishing Ltd
GERD patients ranging from 19% to 71%.29, 32 We
found the prevalence of IBS (>3 Manning criteria) to
be 36% in our cohort of patients with GERD symp-
toms. Our study was not designed to compare the
prevalence of IBS in patients with GERD and the gen-
eral population. Acknowledging this point, our
observed IBS prevalence of 36% in GERD patients
appears to be greater than the IBS prevalence reported
in a recent systematic review for the general popula-
tion (range 4–20%, weighted mean based on seven
studies including 37 501 persons = 12%).29
Psychiatric distress is relatively common in the gen-
eral population and primary care setting. The National
Survey on Drug Use and Health reported that the prev-
alence of ‘serious mental illness’ (defined as being
diagnosed with a mental, behavioural or emotional
disorder using DSM-IV criteria within the past
12 months) was 9.2% in the general US population in
2003.33 In a study which used the PRIME-MD Patient
Health Questionnaire, 825 (28%) of 3000 patients from
eight geographically and economically diverse US pri-
mary care practices qualified for a psychiatric diagno-
sis.34 Considerable overlap between GERD and
psychological distress has also been reported.14–16
Population-based studies have identified psychiatric
disease as a risk factor for GERD symptoms.14–16 A
case–control study found that patients with psychiatric
disease were 2.7 times more likely to report heartburn
than nonpsychiatric controls.15 These studies did not
stratify patients based on the presence or absence of
EO. A small study from Russia recently reported that
patients with endoscopy negative disease were more
likely to exhibit anxiety or hypochondria than patients
with EO.35 In this study, we confirmed the presence of
considerable overlap between GERD and psychological
distress. Forty-one per cent of our GERD patients had
a BSI score of greater than 63 documenting the pres-
ence of significant co-morbid psychological distress.
We did not identify significant differences in the prev-
alence of psychological distress between patients with
EO vs. endoscopy negative disease.
Perhaps the most interesting findings in our study
involved the impact of co-morbid IBS and psychologi-
cal distress on GERD symptoms before and after PPI
therapy. Patients with IBS had more severe GERD
symptoms at baseline, but experienced a magnitude of
improvement in GERD symptoms similar to patients
without IBS after PPI therapy. Before PPI therapy,
GERD patients with IBS also reported a significantly
reduced disease-specific QoL (total QoLRAD and all
subscale scores) compared with GERD patients without
IBS. After PPI therapy, GERD patients with and with-
out IBS enjoyed significant improvements in QoL.
After PPI therapy, there was a trend towards worse
disease-specific QoL as measured by total QoLRAD
score in GERD patients with IBS when compared with
GERD patients without IBS, but observed differences
did not reach statistical significance (P = 0.12).
Co-morbid psychologic distress was independently
associated with more severe GERD symptoms at base-
line, and more residual symptoms after PPI therapy.
Co-morbid psychological distress also predicted a
worse disease-specific QoL (total QoLRAD and all sub-
scale scores) in GERD patients both before and follow-
ing PPI therapy.
To our knowledge, this is the first study to describe
the important effects of co-morbid IBS and psycholog-
ical distress on symptom burden and disease-specific
QoL before and after PPI therapy in patients with
GERD. Regression analyses demonstrate that co-mor-
bid IBS and psychological distress exert independent
effects on symptoms and ⁄ or QoL in GERD patients.
The pathophysiological basis of our findings remains
to be determined. There is a previous work to suggest
that patients with functional dyspepsia and IBS experi-
ence more severe symptoms and are more likely to be
hypersensitive to gastric balloon distention than
patients with functional dyspepsia but no IBS.36 Based
on such data, it is attractive to speculate that our find-
ings may be explained by altered brain–gut interactions
or visceral sensation, features commonly identified in
patients with functional bowel disease.37–39 Further stud-
ies to evaluate these possibilities are eagerly awaited.
We were also interested in investigating whether
there was a difference in symptom severity or QoL in
patients with EO vs. endoscopy negative disease. It has
been suggested that PPI therapy may be less effective
in patients with endoscopy negative disease than in
those with EO.18 This suggestion is intuitively attractive
given the diversity of factors which can contribute to
the development of GERD symptoms in patients with
endoscopy negative disease. For example, recent work
found a reduced likelihood of pathological acid reflux
on ambulatory oesophageal pH monitoring in endos-
copy negative patients compared to those with EO.9
Further, there are some data to suggest that abnormal
oesophageal acid exposure by pH monitoring correlates
with response to PPI therapy in patients with GERD
symptoms.40 Unfortunately, there are virtually no con-
trolled trials which have directly compared symptom
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responses to PPI therapy in patients with endoscopy
negative disease and EO. A recent systematic review18
supports this suggestion but should be viewed as no
more than hypothesis generating.
Our prospective nonrandomized, open label trial
directly compared PPI efficacy in endoscopy negative
and EO patients from the same population. Using
responses to validated disease-specific survey instru-
ments (RDQ, DHSI, QoLRAD), we found no difference
in symptom response or improvements in QoL to PPI
therapy between patients with endoscopy negative dis-
ease and EO. In fact, we found that both groups had a
level of symptoms comparable to a non-GERD popula-
tion after 8 weeks of PPI therapy.23, 24
A number of factors may explain why we found no
difference in treatment response to PPI therapy
between endoscopy negative and EO patients. First, our
study is one of the first to compare directly the efficacy
of PPI therapy in patients with endoscopy negative dis-
ease and EO from the same population. This eliminates
problems attributable to differences in study popula-
tions, methodology, and outcome measures inherent to
the aggregation of data from different studies, as is
done in a systematic review.18 Unlike most previous
studies, we used validated survey instruments and
evaluated changes in survey scores from baseline as
opposed to assessing whether a patient did or did not
have symptoms at the end of therapy. It is unclear how
well responses on integrated symptom surveys corre-
late with a binomial symptom response outcome mea-
sure. We attempted to limit contamination of our study
cohort with patients recently treated with PPI therapy,
which could cause patients with EO to be misclassified
as suffering from NERD. To be eligible for this proto-
col, patients could not have taken a PPI within 2 weeks
of OGD. It could be argued that 2 weeks might not
have been long enough to ensure that a subset of
NERD patients were not in reality patients with healed
EO. However, we would point out that more than 90%
of study participants had either never taken a PPI or
not taken a PPI within a month of their OGD. As such,
we feel that the impact of previous PPI use on our
results was negligible. Further, we did not exclude
patients taking histamine-2 receptor antagonists from
this study. It is possible that a small percentage of
patients with EO could have been misclassified as
endoscopy negative patients related to the use of these
drugs. It is also likely that our study did not have suffi-
cient power to detect a small difference in treatment
response between patients with NERD and patients with
EO. In fact, we fell short of the sample size necessary
to show a 20% difference in PPI response between
patients with EO vs. patients with NERD. Finally, it is
possible that the open label design of our trial may
have inflated treatment responses and obscured small
differences in response rates between groups.
In summary, we found that co-morbid IBS and psy-
chological distress but not the presence or absence of
EO influenced symptom expression and disease-specific
QoL before and after PPI therapy. It is tempting to sug-
gest that co-morbid IBS or psychological distress
reduced the likelihood of GERD symptoms to improve
with PPI therapy. However, we do not feel that our
results support this hypothesis as GERD patients with
these co-morbidities enjoyed degrees of improvement
in GERD symptom burden and disease-specific QoL
similar to patients with no co-morbid IBS or psycholog-
ical distress. The greater symptom burden and reduced
disease-specific QoL at baseline in GERD patients with
IBS or psychological distress tended to translate into
more residual symptoms and lower QoLRAD scores fol-
lowing PPI therapy. These findings can be better under-
stood by considering two persons, person 1 who has a
full glass of water and person 2 who has a half glass of
water. If both persons drink a half glass of water, per-
son 1 will still be left with a half glass of water, while
person 2 will be left with an empty glass. The same
analogy can be applied to GERD patients with co-mor-
bid IBS or psychological distress. While the quantitative
degree of GERD symptom improvement with PPI ther-
apy may be the same, the symptom experience before
and after PPI therapy is often different. Thus, these
findings may provide an explanation for a subset of
patients currently deemed to be ‘PPI failures’ in clinical
practice. Whether the impact of co-morbid IBS and
psychological distress is specific for PPI therapy or
more generalizable to other therapies and conditions is
a question that deserves further study.
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